Bausch + Lomb Corporation (BLCO) Stock
Key stats
- Market cap
- $7.62B
- Price / Earnings ratio
- -68.8x
- EPS (TTM)
- -$0.32
- Volume
- Loading
- 52-week high
- $21.40
- 52-week low
- $14.44
Source: third-party data provider, as of November 13, 2026
Compare with BLCO
Recent news
BLCO vs. HQY: Which Stock Is the Better Value Option?
BLCO vs. HQY: Which Stock Is the Better Value Option?
BLCO
Best Momentum Stock to Buy for November 2nd
Best Momentum Stock to Buy for November 2nd
BLCO
Why Bausch + Lomb (BLCO) is a Top Value Stock for the Long-Term
Why Bausch + Lomb (BLCO) is a Top Value Stock for the Long-Term
BLCO
New Strong Buy Stocks for November 2nd
New Strong Buy Stocks for November 2nd
BLCONews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 74.44
- MACD 12/26/9
- 1.05
- EMA 9 of MACD
- 0.82
- MACD histogram
- 0.23
- SMA 50
- $17.86
- Price above SMA 50
- EMA 50
- $18.24
- Price above EMA 50
- SMA 200
- $16.81
- Price above SMA 200
- EMA 200
- $17.10
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 8 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news
BLCO vs. HQY: Which Stock Is the Better Value Option?
BLCO vs. HQY: Which Stock Is the Better Value Option?
BLCOBest Momentum Stock to Buy for November 2nd
Best Momentum Stock to Buy for November 2nd
BLCOWhy Bausch + Lomb (BLCO) is a Top Value Stock for the Long-Term
Why Bausch + Lomb (BLCO) is a Top Value Stock for the Long-Term
BLCONew Strong Buy Stocks for November 2nd
New Strong Buy Stocks for November 2nd
BLCO
Bausch + Lomb Announces Publication of Multinational Survey Results Highlighting the Burden of Dry Eye Symptoms and Opportunities for Improved Awareness and Patient Education
Bausch + Lomb Announces Publication of Multinational Survey Results Highlighting the Burden of Dry Eye Symptoms and Opportunities for Improved Awareness and Patient Education
BLCO
What Bausch + Lomb (BLCO) Said on Its Q3 Earnings Call
What Bausch + Lomb (BLCO) Said on Its Q3 Earnings Call
BLCO
Bausch + Lomb (BLCO) Surpasses Q3 Earnings and Revenue Estimates
Bausch + Lomb (BLCO) Surpasses Q3 Earnings and Revenue Estimates
BLCO
Bausch + Lomb Posts Strong Third-Quarter Performance, Raises Full-Year 2026 Guidance
Bausch + Lomb Posts Strong Third-Quarter Performance, Raises Full-Year 2026 Guidance
BLCO
Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance
Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance
BLCO
Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting
Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting
BLCONews tone: automated (AI) classification of the article's content, not a price prediction.
About Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Brenton L. Saunders J.D. | CEO & Director | 1970 |
| Mr. Osama A. Eldessouky | Executive VP & CFO | 1972 |
| Mr. A. Robert D. Bailey | Executive VP & Chief Legal Officer | 1963 |
| Dr. Yehia Hashad M.D., Ph.D. | Executive VP of Research & Development and Chief Medical officer | 1968 |
| Mr. Andrew J. Stewart | President of Global Pharmaceuticals & International Consumer | 1976 |
| Mr. Alan Waterhouse CPFA, MBA | Executive VP and Chief Supply Chain & Operations Officer | 1960 |
| Mr. Frederick J. Munsch | Senior VP, Controller & Chief Accounting Officer | 1970 |
| Mr. George Gadkowski | VP & Head of Investor Relations & Business Insights | — |
| Mr. Jonathon L. Kellerman | Chief Compliance Officer | — |
| Mr. T.J. Crawford | Chief Communications Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 74.44
- MACD 12/26/9
- 1.05
- EMA 9 of MACD
- 0.82
- MACD histogram
- 0.23
- SMA 50
- $17.86
- Price above SMA 50
- EMA 50
- $18.24
- Price above EMA 50
- SMA 200
- $16.81
- Price above SMA 200
- EMA 200
- $17.10
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
8 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $19.00
- Average
- $22.43
- High
- $24.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -7.7 | -4.7 | -4.0 | +7.6 | +2.2 | +4.2 | -4.9 | +18.1 | +6.5 |
